Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.72 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.72 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.72 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.72 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.72 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.72 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 5/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019415 | 0.86 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3030544 | 0.85 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3031295 | 0.85 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029467 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029333 | 0.83 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3023179 | 0.83 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3027747 | 0.81 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3032808 | 0.81 | PSEN1 (0.81) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8148492 | 0.80 | PSEN1 (0.85) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3030062 | 0.80 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | PSEN1, PSEN2, APP | PSEN1 1/4885PSEN2 2/4885APH1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.